AA
MRSN

ALPS Advisors’s Mersana Therapeutics MRSN Stock Holding History

ALPS Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,557
Closed -$113K – 997
2023
Q3 		$113K Buy
3,557
+194
+6% +$9.22K ﹤0.01% 969
2023
Q2 		$277K Buy
3,363
+516
+18% +$75.5K ﹤0.01% 918
2023
Q1 		$293K Buy
2,847
+138
+5% +$19.4K ﹤0.01% 904
2022
Q4 		$397K Buy
+2,709
New +$458K ﹤0.01% 680

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ALPS Advisors's MRSN Position: Q4 2023 in Review

ALPS Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 3,557 shares — an estimated $113K sold.

ALPS Advisors first reported a position in MRSN in Q4 2022 and held it in 4 quarters. The position peaked at $397K in Q4 2022. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • ALPS Advisors reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 3,557 Mersana Therapeutics shares in Q4 2023, an estimated $113K.
  • ALPS Advisors first reported a position in Mersana Therapeutics in Q4 2022 and held it in 4 quarters.
  • ALPS Advisors's Mersana Therapeutics position peaked at $397K in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.